{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:11Z","timestamp":1787595731838,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clml.2021.08.005","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T14:41:18Z","timestamp":1630161678000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study"],"prefix":"10.1016","volume":"22","author":[{"given":"Larry W.","family":"Kwak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Manuel","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-5052","authenticated-orcid":false,"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayane","family":"Tumyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Menne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Ilyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"Lopez Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Samoilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvard","family":"Zhavrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ya\u00f1ez Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-5338","authenticated-orcid":false,"given":"Keum Young","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.08.005_bib0001","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.08.005_bib0002","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2021.08.005_bib0003","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.08.005_bib0004","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): B-cell lymphomas. Version 4. 2021. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed: July 28, 2021."},{"key":"10.1016\/j.clml.2021.08.005_bib0005","unstructured":"European Medicines Agency. Truxima summary of product characteristics. 2021. Accessed from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/truxima-epar-product-information_en.pdf. Accessed: July 28, 2021."},{"key":"10.1016\/j.clml.2021.08.005_bib0006","unstructured":"US Food and Drug Administration. Truxima prescribing information. 2020. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761088s009lbl.pdf. Accessed: July 28, 2020."},{"key":"10.1016\/j.clml.2021.08.005_bib0007","doi-asserted-by":"crossref","unstructured":"Kim WS, Coiffier B, Kwon H-C, Kim S. Clinical development of CT-P10 and other biosimilar cancer therapeutics. 2017;13(15s):31\u201344. doi:10.2217\/fon-2017-0155.","DOI":"10.2217\/fon-2017-0155"},{"key":"10.1016\/j.clml.2021.08.005_bib0008","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14712598.2019.1665018","article-title":"Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis","volume":"19","author":"Jung","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clml.2021.08.005_bib0009","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s12325-017-0522-y","article-title":"The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries","volume":"34","author":"Gulacsi","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2021.08.005_bib0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40259-017-0233-6","article-title":"Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: Results of a 56-week open-label study in patients with rheumatoid arthritis","volume":"31","author":"Park","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.clml.2021.08.005_bib0011","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/rheumatology\/kez152","article-title":"Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial","volume":"58","author":"Shim","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.clml.2021.08.005_bib0012","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomized, double-blind, parallel-group, phase 3 trial","volume":"5","author":"Ogura","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.08.005_bib0013","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.005_bib0014","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.005_bib0015","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.08.005_bib0016","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol E4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.005_bib0017","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.005_bib0018","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40259-019-00398-7","article-title":"A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera\u00ae) in subjects with previously untreated CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL)","volume":"34","author":"Sharman","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.clml.2021.08.005_bib0019","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2019-126379","article-title":"Long-term efficacy and safety results of CT-P10 and reference rituximab in patients with newly diagnosed advanced stage follicular lymphoma: phase III updated study results with median follow-up of 40 months","volume":"134 (Suppl 1)","author":"Buske","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.005_bib0020","unstructured":"US Food and Drug Administration. Rituxan prescribing information. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5464lbl.pdf. Accessed: July 28, 2021."},{"key":"10.1016\/j.clml.2021.08.005_bib0021","unstructured":"European Medicines Agency. MabThera summary of product characteristics. 2021. Accessed from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf. Accessed: July 28, 2021."},{"key":"10.1016\/j.clml.2021.08.005_bib0022","doi-asserted-by":"crossref","first-page":"e000460","DOI":"10.1136\/esmoopen-2018-000460","article-title":"Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology","volume":"4","author":"Giuliani","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.clml.2021.08.005_bib0023","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.clinthera.2018.03.018","article-title":"Monoclonal antibody biosimilars in oncology: critical appraisal of available data on switching","volume":"40","author":"Declerck","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2021.08.005_bib0024","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1080\/10428194.2020.1742906","article-title":"The clinical outcomes of rituximab biosimilar CT-P10 (Truxima\u00ae) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience","volume":"61","author":"Lee","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:24Z","timestamp":1761871104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021003621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2152265021003621"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}